Belagenpumatucel-L

Summary

Belagenpumatucel-L (CHEMBL2108577) is a phase-3 clinical-stage cell; indicated across 2 conditions including carcinoma and lung neoplasm.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Cell
• Indications: 2 conditions

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2108577
Name	Belagenpumatucel-L
Type	Cell
Max phase	3

Also known as: Belagenpumatucel-l, BELAGENPUMATUCEL-L

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
carcinoma	2	MONDO:0004993	EFO:0000313
lung neoplasm	2	MONDO:0021117	MONDO:0021117

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).